Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158019929> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2158019929 endingPage "70" @default.
- W2158019929 startingPage "3965" @default.
- W2158019929 abstract "We present our experience with a combination chemotherapy regimen consisting of ranimustine (MCNU) and recombinant human mutant tumor necrosis factor-alpha (TNF-SAM2) for malignant astrocytomas. The initial regimens were prescribed as adjuvant therapy in conjunction with radiotherapy following standard surgical treatment. Newly diagnosed patients were treated with up to four cycles of this regimen (TNF-SAM2, MCNU, and radiotherapy: TMR group). Seventeen patients (11 men and 6 women) aged 24 to 68 years (median 54.6 years) were eligible and evaluated for response and toxicity. The estimated median survival time was 354 weeks with anaplastic astrocytomas, and 76 weeks with glioblastomas. One- and 2-year survival rates were 100% and 100% with anaplastic astrocytomas, and 69.2% and 29.7% with glioblastomas. Grade 3 and 4 hematological toxicities were not experienced. None of the patients experienced a treatment delay due to toxicity. All other acute toxicities were anticipated and manageable. Twenty three patients (11 men and 12 women) aged 22 to 66 years (median 50.7 years) were evaluated as a historical control of patients who received chemotherapy with MCNU alone in conjunction with radiotherapy following standard surgical treatment (MCNU and radiotherapy: MR group). The estimated median survival time was 205 weeks with anaplastic astrocytomas, and 62 weeks with glioblastomas. One- and 2-year survival rates were 88.9% and 66.7% with anaplastic astrocytomas, and 71.4% and 7.1% with glioblastomas in this group. There were no significant differences in survival rates between patients in the TMR and MR groups with either anaplastic astrocytoma or glioblastoma. However, despite the small number of patients, those with anaplastic astrocytoma in the TMR group tended to survive longer than those in the MR group. These results suggest that combined chemotherapy with mutant TNF-alpha may benefit those with anaplastic astrocytoma, and thus warrants further evaluation. On the other hand, the lack of activity does not warrant any further study of this schedule of TNF-SAM2 for the treatment of glioblastoma." @default.
- W2158019929 created "2016-06-24" @default.
- W2158019929 creator A5000300977 @default.
- W2158019929 creator A5005767516 @default.
- W2158019929 creator A5039724857 @default.
- W2158019929 creator A5058435450 @default.
- W2158019929 creator A5080851138 @default.
- W2158019929 creator A5083333493 @default.
- W2158019929 creator A5089936458 @default.
- W2158019929 date "1998-12-17" @default.
- W2158019929 modified "2023-09-23" @default.
- W2158019929 title "Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2)." @default.
- W2158019929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9854511" @default.
- W2158019929 hasPublicationYear "1998" @default.
- W2158019929 type Work @default.
- W2158019929 sameAs 2158019929 @default.
- W2158019929 citedByCount "3" @default.
- W2158019929 countsByYear W21580199292020 @default.
- W2158019929 countsByYear W21580199292022 @default.
- W2158019929 crossrefType "journal-article" @default.
- W2158019929 hasAuthorship W2158019929A5000300977 @default.
- W2158019929 hasAuthorship W2158019929A5005767516 @default.
- W2158019929 hasAuthorship W2158019929A5039724857 @default.
- W2158019929 hasAuthorship W2158019929A5058435450 @default.
- W2158019929 hasAuthorship W2158019929A5080851138 @default.
- W2158019929 hasAuthorship W2158019929A5083333493 @default.
- W2158019929 hasAuthorship W2158019929A5089936458 @default.
- W2158019929 hasConcept C126322002 @default.
- W2158019929 hasConcept C141071460 @default.
- W2158019929 hasConcept C143998085 @default.
- W2158019929 hasConcept C2776694085 @default.
- W2158019929 hasConcept C2777982462 @default.
- W2158019929 hasConcept C2778227246 @default.
- W2158019929 hasConcept C2778336483 @default.
- W2158019929 hasConcept C2778880634 @default.
- W2158019929 hasConcept C2779083369 @default.
- W2158019929 hasConcept C2781413609 @default.
- W2158019929 hasConcept C502942594 @default.
- W2158019929 hasConcept C509974204 @default.
- W2158019929 hasConcept C71924100 @default.
- W2158019929 hasConcept C90924648 @default.
- W2158019929 hasConceptScore W2158019929C126322002 @default.
- W2158019929 hasConceptScore W2158019929C141071460 @default.
- W2158019929 hasConceptScore W2158019929C143998085 @default.
- W2158019929 hasConceptScore W2158019929C2776694085 @default.
- W2158019929 hasConceptScore W2158019929C2777982462 @default.
- W2158019929 hasConceptScore W2158019929C2778227246 @default.
- W2158019929 hasConceptScore W2158019929C2778336483 @default.
- W2158019929 hasConceptScore W2158019929C2778880634 @default.
- W2158019929 hasConceptScore W2158019929C2779083369 @default.
- W2158019929 hasConceptScore W2158019929C2781413609 @default.
- W2158019929 hasConceptScore W2158019929C502942594 @default.
- W2158019929 hasConceptScore W2158019929C509974204 @default.
- W2158019929 hasConceptScore W2158019929C71924100 @default.
- W2158019929 hasConceptScore W2158019929C90924648 @default.
- W2158019929 hasIssue "5D" @default.
- W2158019929 hasLocation W21580199291 @default.
- W2158019929 hasOpenAccess W2158019929 @default.
- W2158019929 hasPrimaryLocation W21580199291 @default.
- W2158019929 hasRelatedWork W2016210063 @default.
- W2158019929 hasRelatedWork W2086955530 @default.
- W2158019929 hasRelatedWork W2091720821 @default.
- W2158019929 hasRelatedWork W2143178874 @default.
- W2158019929 hasRelatedWork W2158019929 @default.
- W2158019929 hasRelatedWork W2359366932 @default.
- W2158019929 hasRelatedWork W2388730008 @default.
- W2158019929 hasRelatedWork W3215662100 @default.
- W2158019929 hasRelatedWork W4224862170 @default.
- W2158019929 hasRelatedWork W4253125675 @default.
- W2158019929 hasVolume "18" @default.
- W2158019929 isParatext "false" @default.
- W2158019929 isRetracted "false" @default.
- W2158019929 magId "2158019929" @default.
- W2158019929 workType "article" @default.